We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 3,138

Washington Healthcare Update - Jun 4, 2018
  • McGuireWoods LLP
  • USA
  • June 4 2018

In a series of interviews during the recess week, Senate Majority Leader Mitch McConnell has described what he expects the Senate to act on. McConnell


India: Impact of proposed EU IPR enforcement mechanism on the growth of Indian generic drugs
  • SS Rana & Co
  • India
  • June 4 2018

India is one of the largest suppliers of low cost generic medicines in the world. The use of generic medicines, in comparison with their branded


Methods of Treatment Survive Another 101 Challenge - Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd.
  • K&L Gates
  • USA
  • May 31 2018

On May 15, in Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd., the U.S. District Court for the District of Delaware upheld two sets of


Proposed national pharmacare programme and prescription and generic drug pricing modifications
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • May 30 2018

Unlike many Organisation for Economic Cooperation and Development member countries, Canada has no national pharmacare programme (ie, a single system


Federal Circuit Issues Two Decisions Impacting Standing to Challenge Validity of Pharma Patents
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • May 23 2018

Two recent Federal Circuit decisions address when a party has standing to challenge the validity of a patent. Though the cases arose in different


Washington Healthcare Update - May 21, 2018
  • McGuireWoods LLP
  • USA
  • May 21 2018

On May 17, the Energy and Commerce Committee held the second of its opioid legislation markups, clearing 32 bills. The previous markup reported out 25


ML Strategies Health Care Preview - Week of May 21st
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • May 21 2018

This week, various health care programs in need of reauthorization will be reviewed by the relevant House and Senate Committees. The Senate will be


ITC Institutes Investigation Based on Allegation of Drug Sales Without FDA Approval
  • Jones Day
  • USA
  • May 17 2018

Normally, it is the FDA that monitors the improper distribution of drugs. But, as it turns out, the International Trade Commission ("ITC") might be


FDA Publishes List of Drug Companies Accused of Hindering Generic Entry: Antitrust Implications
  • Wilmer Cutler Pickering Hale and Dorr LLP
  • USA
  • May 17 2018

Today, as part of the Trump Administration's stated goal to lower drug prices, the Food and Drug Administration (FDA) published a list of


Standing Committee on Health proposes National Pharmacare program, modifications to prescription and generic drug pricing
  • Smart & Biggar/Fetherstonhaugh
  • OECD, Canada
  • April 27 2018

While common among member countries of the Organisation for Economic Co-operation and Development (OECD), Canada does not have a national pharmacare